Phase I Trial of Sunitinib Plus Temsirolimus in Patients With Metastatic Renal Cell Cancer.

Trial Profile

Phase I Trial of Sunitinib Plus Temsirolimus in Patients With Metastatic Renal Cell Cancer.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2014

At a glance

  • Drugs Sunitinib (Primary) ; Temsirolimus (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Feb 2014 Interim results presented at the 2014 Genitourinary Cancers Symposium.
    • 01 Feb 2014 Status changed from active, no longer recruiting to discontinued.
    • 02 Apr 2013 Planned End Date changed from 1 May 2014 to 1 May 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top